ABUS
Arbutus Biopharma Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website arbutusbio.com
- Employees(FY) 96
- ISIN CA03879J1003
Performance
+1.36%
1W
+2.05%
1M
+2.76%
3M
+61.08%
6M
+19.2%
YTD
+18.25%
1Y
Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Investment Analysis Report: ABUS
Overview
ABUS is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $486.32 million. In this report, we will conduct a comprehensive analysis of ABUS focusing on valuation, financial health, earnings and revenue grow...
Technical Analysis of ABUS 2024-05-10
Overview:
In analyzing the technical indicators for ABUS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2024-05-17 12:03
- 2024-05-17 10:40
- 2024-05-17 09:00
- 2024-05-16 21:00
- 2024-05-07 07:30
Arbutus to Participate in Two Upcoming Investor Conferences(GlobeNewswire)
- 2024-05-06 19:30
Arbutus to Participate in Two Upcoming Investor Conferences(Globenewswire)
- 2024-05-03 11:19
- 2024-05-03 06:39
- 2024-05-03 03:24
- 2024-05-02 08:45
- 2024-05-02 07:44
Arbutus: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-02 07:30
- 2024-05-02 07:25
- 2024-05-02 00:55
- 2024-05-01 20:58
- 2024-05-01 20:45
- 2024-05-01 19:30
- 2024-05-01 19:25
- 2024-04-30 09:40
- 2024-04-29 21:40
- 2024-04-18 07:30
- 2024-04-17 19:30
- 2024-04-04 08:30
- 2024-04-03 20:30
- 2024-04-01 12:44
- 2024-03-08 07:30
Arbutus to Participate in Two Upcoming Investor Conferences(GlobeNewswire)
- 2024-03-07 18:30
Arbutus to Participate in Two Upcoming Investor Conferences(Globenewswire)
- 2024-03-03 07:38
- 2024-03-02 07:29
- 2024-02-29 23:14
Q4 2023 Arbutus Biopharma Corp Earnings Call(Thomson Reuters StreetEvents)
Page 1 of 5
previousnext